Double-blind olanzapine vs. haloperidol D2 dopamine receptor blockade in schizophrenic patients: A baseline-endpoint [123I]IBZM SPECT study

Psychiatry Research - Neuroimaging

Volumn 107, Issue 2, 2001, Pages 87-97

  Bernardo, Miquel ^a   Parellada, Eduard ^a   Lomea, Francisco ^a   Catafau, Ana M ^b   Font, Mireia ^a   Gómez, Juan C ^c   López Carrero, Carmen ^c   Gutiérrez, Fernando ^a   Pavía, Javier ^a   Salamero, Manel ^a  

^a HOSPITAL CLÍNIC   (Spain)

^b HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^c DCRandT   (Spain)

Author keywords

Benzamides; D2 dopamine receptor; Olanzapine; Psychosis; Single Photon Emission Computed Tomography

Indexed keywords

DOPAMINE 2 RECEPTOR; HALOPERIDOL; IODINE 123; N [(1 ETHYL 2 PYRROLIDINYL)METHYL] 2,3 DIHYDRO 5 IODOBENZOFURAN 7 CARBOXAMIDE; OLANZAPINE;

ADULT; ANALYTIC METHOD; ARTICLE; BASAL GANGLION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; EXTRAPYRAMIDAL SYMPTOM; FEMALE; FRONTAL CORTEX; HUMAN; IMAGE ANALYSIS; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECEPTOR OCCUPANCY; SCHIZOPHRENIA; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TREATMENT OUTCOME;

EID: 0035949138     PISSN: 09254927     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0925-4927(01)00085-3     Document Type: Article

References (41)

1. A rating scale for drug-induced akathisia
2. In vivo occupancy of striatal and temporal cortical D2/D3 dopamine receptors by typical antipsychotic drugs. [123-I]epidepride single photon emission tomography (SPECT) study
3. Striatal and temporal cortical D2/D3 receptor occupancy by olanzapine and sertindole in vivo: A [123-I]epidepride single photon emission tomography (SPECT) study
4. 123I IBZM single photon emission tomography (SPET) study
5. Radioreceptor binding profile of the atypical antipsychotic olanzapine
6. Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine: Relation to extrapyramidal side effects
7. 125I) epidepride
8. Instrumentation for brain SPET: Guidelines and quantification
9. 5-HT2 and D2 receptor occupancy of olanzapine in schizophrenia: A PET investigation
10. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia
11. 123I]IBZM SPECT for imaging of striatal D2 dopamine receptors in 56 schizophrenic patients taking various neuroleptics
12. Extrapyramidal side effects with risperidone and haloperidol at comparable D2 receptor occupancy levels
13. IBZM SPECT imaging of striatal dopamine-2 receptors in psychotic patients treated with the novel antipsychotic substance quetiapine in comparison to clozapine and haloperidol
14. 2 receptor occupancy by olanzapine or risperidone in young patients with schizophrenia
15. Interaction of antipsychotic drugs with neurotransmitter receptor sites in vitro and in vivo in relation to pharmacological and clinical effects: Role of 5HT2 receptors
16. Preparation of (Br-76)FLB 457 and (Br-76)FLB 463 for examination of striatal and extrastriatal dopamine D2 receptors with PET
17. 76Br) bromospiperone in untreated schizophrenic patients
18. The mechanism of action of novel antipsychotic drugs
19. Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: A double-blind PET study of schizophrenic patients
20. A PET study of 5-HT2 and D2 dopamine receptor occupancy induced by olanzapine in healthy subjects
21. The Brief Psychiatric Rating Scale
22. Validación de la escala de los síndromes positivo y negativo (PANSS)
23. Individual variation in D2 dopamine receptor occupancy in clozapine-treated patients
24. Clozapine, single photon emission tomography, and the D2 dopamine receptor blockade hypothesis of schizophrenia
25. 123I]IBZM single photon emission tomography (SPET) study
26. 123I]IBZM single photon emission tomography (SPET) study
27. Limbic selectivity of clozapine
28. In vivo determination of striatal dopamine D2 receptor occupancy in patients treated with olanzapine
29. In vivo olanzapine occupancy of muscarinic acetylcholine receptors in patients with schizophrenia
30. D2-dopamine receptor occupancy differs between patients with and without extrapyramidal side effects
31. 123I]IBZM SPECT in patients treated with typical and atypical neuroleptics: Relationship to drug plasma levels and extrapyramidal side effects
32. Chemical brain anatomy in schizophrenia
33. Dopamine receptors and psychosis
34. 123I]IBZM
35. A rating scale for extrapyramidal side effects
36. Striatal and extra-striatal D(2)/D(3) dopamine receptor occupancy by quetiapine in vivo. [(123)I]-epidepride single photon emission tomography (SPECT) study
37. 123I]IBZM SPECT imaging of striatal dopamine-2 receptor occupancy in schizophrenic patients treated with olanzapine in comparison to clozapine and haloperidol
38. 5-HT2A receptor blockade in patients with schizophrenia treated with risperidone or clozapine
39. Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine
40. Imaging neurotransmission and neuroreceptors: Physiological and pharmacological basis